A recent study identified an increasing inclusion rate of individuals with HIV in clinical trials of anti–programmed cell death protein 1 and anti–programmed death ligand 1 (anti–PD-1/PD-L1) therapy for patients with cancer, in accordance with efforts of the Cancer Therapy Evaluation Program (CTEP) of the National Cancer Institute. "Anti–PD-1 and anti–PD-L1 immune checkpoint blockade (ICB) constitutes the therapeutic backbone for multiple malignant neoplasms," write the authors, led by Josh...